Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 27, 2015 8:31 PM ET


Company Overview of Jounce Therapeutics, Inc.

Company Overview

Jounce Therapeutics, Inc. engages in the discovery and development of a pipeline of cancer immunotherapy treatments for a range of cancers. Its immunotherapies are designed to harness the patient's immune system to seek out and attack cancerous cells and tumors. The company was incorporated in 2012 and is based in Cambridge, Massachusetts.

1030 Massachusetts Avenue

Cambridge, MA 02138

United States

Founded in 2012





Key Executives for Jounce Therapeutics, Inc.

Chief Executive Officer
Age: 56
Compensation as of Fiscal Year 2015.

Jounce Therapeutics, Inc. Key Developments

Jounce Therapeutics Appoints Duncan Higgons to its Board of Directors

Jounce Therapeutics, Inc. announced Duncan Higgons has been appointed to the company’s board of directors. Mr. Higgons has served as the chief operating officer at Agios Pharmaceuticals since 2009.

Jounce Therapeutics, Inc. Appoints Elizabeth Trehu as Chief Medical Officer

Jounce Therapeutics, Inc. announced the appointment of Elizabeth Trehu, M.D., to the position of chief medical officer. Dr. Trehu brings to Jounce more than 25 years of clinical experience, including nearly 15 years in the biotech industry leading translational and integrated hematology and oncology drug development. Dr. Trehu joins the company from Promedior, Inc., where she served as the chief medical officer. In this role, she was responsible for clinical development, clinical operations, regulatory affairs, quality assurance and program management, and led the creation and mplementation of clinical development plans for Promedior’s lead product candidate. Prior to Promedior, Dr. Trehu served as vice president, oncology product development and medical affairs for Infinity Pharmaceuticals, and earlier held various leadership positions at Genzyme Corporation, including vice president and general manager of hematology for Genzyme’s transplant oncology group. Earlier in her career, Dr. Trehu held roles of increasing responsibility at Millennium Pharmaceuticals, including vice president, oncology global medical affairs, and was integral in the development and commercialization of VELCADE. As an assistant professor of medicine at Tufts University School of Medicine, Dr. Trehu conducted preclinical and clinical research in immunotherapy with the NCI Cytokine Working Group.

Jounce Therapeutics, Inc. Presents at Leerink Partners Immuno-Oncology Roundtable, Oct-01-2015 01:30 PM

Jounce Therapeutics, Inc. Presents at Leerink Partners Immuno-Oncology Roundtable, Oct-01-2015 01:30 PM. Venue: Le Parker Meridien Hotel, New York, New York, United States. Speakers: Richard Murray, Chief Executive Officer.

Similar Private Companies By Industry

Company Name Region
Drug Source Company, LLC United States
Taisho Pharmaceutical R&D Inc. United States
Bachem, Inc. United States
Soft Gel Technologies, Inc. United States
Aquavit Pharmaceuticals, Inc. United States

Recent Private Companies Transactions

Private Placement
April 17, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Jounce Therapeutics, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at